Clinical trial manufacturing is becoming increasingly demanding.
Small batch sizes, short timelines, potent or sterile products and strict regulatory expectations require manufacturing environments that are both highly controlled and flexible.
In this context, isolation technologies are playing a central role.
A concrete example is provided by Eramol, recently featured in BusinessFocus Healthcare & Pharmaceutical, where isolator‑based solutions support clinical manufacturing activities.
In this project, IWT acts as a technology partner, providing the ASEPTICARE isolator to support aseptic and high‑containment operations.
Why isolation is critical in clinical manufacturing
Clinical manufacturing combines several challenges:
Traditional cleanroom approaches often rely heavily on manual operations and operator presence, increasing variability and contamination risk.
Isolation systems address these challenges by:
Asepticare in a real clinical manufacturing environment
The ASEPTICARE isolator implemented at Eramol supports aseptic operations within a controlled clinical manufacturing setup.
Its role is to ensure:
The images published in the BusinessFocus feature show a modern isolator‑based environment designed to manage complexity without compromising control.
This is not a conceptual design, but a real manufacturing application.
From clinical manufacturing to advanced therapies
The same drivers observed in clinical manufacturing are also shaping ATMP environments.
Cell and gene therapies introduce additional complexity:
Isolation technologies provide a common foundation across clinical and ATMP manufacturing, supporting scalability while maintaining containment and aseptic assurance.
Isolation as a strategic manufacturing choice
Isolation is no longer adopted only to “meet requirements”.
For manufacturers like Eramol, it becomes a strategic choice to:
Well‑designed isolation systems allow manufacturers to evolve from clinical development toward more structured production stages without redesigning the entire facility.
IWT’s approach
At IWT, we support pharmaceutical manufacturers through isolation solutions designed for real manufacturing needs, not just specifications.
Our role as a technology partner focuses on:
Conclusion
The Eramol project clearly shows how isolation technologies are already enabling controlled and compliant clinical manufacturing.
As pharmaceutical production models continue to evolve, isolator‑based environments such as ASEPTICARE play a key role in bridging innovation and control.
CORPORATE
ITALY
FRANCE
GERMANY
UK
CHINA